Insights for health care providers
Answering your questions about the MyUTI Test
The MyUTI Test is a CLIA-certified laboratory test supported by GoPath Laboratories, a state-of-the-art, CAP-accredited and CLIA-certified lab providing diagnostic testing for clinicians, hospital systems and pharmaceutical firms.
How does this test differ from a standard urine culture?
The standard urine culture is used to match known bacterial genomes to identify species of bacteria, most notably E.coli.
The MyUTI Test identifies the top 12 uropathogens shown to cause recurrent urinary tract infections and symptomatology. Gram-positive and gram-negative bacteria, fungus and resistance genes are detected within a single sample. To support antibiotic stewardship, a comprehensive infectious disease clinical decision support tool provides clinicians with treatment recommendations based on findings.
Why will this additional data help in diagnosing certain patients?
Reliable studies show that up to 40% of patients with negative, sub-diagnostic or natural flora results on urine cultures do actually have a pathogenic UTI. Often, these patients are not treated and continue to suffer. The MyUTI Test provides greater detail to support diagnosis and effective treatment, especially in cases where multiple pathogens may be driving a UTI.
AUA guidelines on recurrent uncomplicated UTIs state that microbial confirmation at the time of acute-onset, urinary-tract-associated symptoms and signs is an important element in establishing a diagnosis of rUTI. The guidelines recommend that clinicians obtain robust diagnostics with each symptomatic acute cystitis episode prior to initiating treatment in patients with rUTIs .
What lab technology supports the MyUTI Test?
The MyHome UTI Test is a PCR-based genomic test specially designed to identify 12 uropathogens (bacterial and fungal) that studies show are most frequently involved in UTIs, along with 3 antibiotic resistance genes. This technology is widely trusted and used in many urology specialty practices across the U.S.
The MyUTI Test also uses the powerful Arkstone reporting and clinical decision support tool for informed antibiotic selection. Learn more here.
What is provided in the Arkstone OneChoice report?
Arkstone technology combines machine-learning artificial intelligence with decades of deep infectious disease expertise to guide physicians to a singular treatment regimen that targets the most relevant infection with the lowest risk to the patient. More information about Arkstone’s OneChoice Report can be found in this video.
Supporting Patients With Advanced Testing
Expanded diagnostic capabilities to reliably manage and treatment of recurrent urinary tract infections
Join The Network
Sign up with your email address to receive news, share your opinion, or participate in clinical roundtables.
Additional references:
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
Xu R, Deebel N, Casals R, Dutta R, Mirzazadeh M. A New Gold Rush: A Review of Current and Developing Diagnostic Tools for Urinary Tract Infections. Diagnostics (Basel). 2021 Mar 9;11(3):479. doi: 10.3390/diagnostics11030479. PMID: 33803202; PMCID: PMC7998255.
Price TK, Dune T, Hilt EE, et al.The clinical urine culture: enhanced techniques improve detection of clinically relevant microorganisms.J Clin Microbiol. 2016; 54: 1216-1222 https://doi.org/10.1128/JCM.00044-16
N. Luke, D. Baunoch. After 180 Years, Is it Time for Something Better for Diagnosing UTI’s?. JOJ Urology & Nephrology, 2020; 7(2): 555714. DOI: 10.19080/JOJUN.2020.07.555714
Hilt EE, McKinley K, Pearce MM, et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol. 2014;52(3):871-876. doi:10.1128/JCM.02876-13
Wojno K, Bounach D, Luke N, et al. Multiplex PCR Based Urinary Tract Infection (UTI) Analysis Compared to Traditional Urine Culture in Identifying Significant Pathogens in Symptomatic Patients. 2019 https://doi.org/10.1016/j.urology.2019.10.018